The therapeutic benefits of psychedelic medicines may not require the psychoactive effects. The post To Trip or Not to Trip? Why Non-Hallucinogenic Treatments...
The article Cybin Selects Generalized Anxiety Disorder for DMT Drug CYB-004 was originally published on Microdose. Cybin has selected Generalized Anxiety...
Modern psychiatry and research did not "discover" psychedelics for mental health. The post How Indigenous Knowledge About Psychedelic Plants Can Shape...
The article Key Takeaways from MindMed’s 2023 Corporate Update was originally published on Microdose. On January 9th, psychedelic medicine company MindMed (Nasdaq:...
You may know Psychedelic Invest for our trackable index of public companies. You may know us for our constant stream of informative content surrounding...
The article A Deeper Look at atai Life Sciences’ Company Update was originally published on Microdose. atai Life Science has released its most recent...
Moderna CEO Stéphane Bancel is revving the engines going into 2023, with a whopping $4.5 billion R&D budget and a new priority review voucher. The...
MAPS Policy Director Ismail Alitalks what it means for the psychedelics industry. The post Congress Hops on Psychedelics Juggernaut with a New Caucus appeared...
I am optimistic that the market will perform better in 2023 and think the sell-off could be a great opportunity to invest in some of those...
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced the distribution...